TABLE 3.
Baseline characteristics
| Total | Intervention | Controls | |
|---|---|---|---|
| n | 146 | 73 | 73 |
| Age | 56.8 ± 9.2 | 56.9 ± 8.9 | 56.7 ± 9.4 |
| Male | 98 (67) | 48 (66) | 50 (69) |
| Body weight | 71.3 ± 14 | 71.6 ± 15 | 71.0 ± 13 |
| BMI, kg/m2 | 25.7 ± 3.8 | 26.1 ± 4.2 | 25.4 ± 3.3 |
| Waist circumference | 91.6 ± 10 | 92.0 ± 10.8 | 91.2 ± 9.4 |
| Comorbidities, n (%) | |||
| Diabetes mellitus | 35 (24) | 21 (29) | 14 (19) |
| Dyslipidemia | 67 (46) | 30 (41) | 37 (51) |
| Cerebrovascular disease | 2 (1) | 2 (3) | 0 (0) |
| Chronic kidney disease | 11 (8) | 7 (10) | 4 (6) |
| Antihypertensive drugs, n (%) | 80 (55) | 40 (55) | 40 (55) |
| ACE inhibitor | 4 (3) | 4 (5) | 0 (0) |
| ARB | 47 (32) | 23 (32) | 24 (33) |
| Beta‐blocker | 6 (4) | 2 (3) | 4 (6) |
| CCB | 65 (45) | 33 (45) | 32 (44) |
| Diuretic | 4 (3) | 2 (3) | 2 (3) |
| SGLT2 inhibitor | 11 (8) | 7 (10) | 4 (6) |
| SBP | |||
| ABPM (24 hours) | 136.9 ± 12.5 | 138.4 ± 11.6 | 135.4 ± 13.2 |
| ABPM (daytime) | 142.1 ± 12.2 | 143.6 ± 11.1 | 140.6 ± 13.1 |
| ABPM (bedtime) | 127.3 ± 15.3 | 129.2 ± 13.9 | 125.4 ± 16.5 |
| Office | 145.2 ± 13.8 | 146.4 ± 13.3 | 144.0 ± 14.2 |
| Home | 143.9 ± 9.7 | 144.0 ± 8.1 | 143.8 ± 11.2 |
| DBP | |||
| ABPM (24 hours) | 87.3 ± 8.8 | 87.7 ± 8.9 | 86.9 ± 8.8 |
| ABPM (daytime) | 90.7 ± 9.4 | 90.9 ± 9.1 | 90.6 ± 9.8 |
| ABPM (bedtime) | 80.8 ± 9.9 | 81.9 ± 10.3 | 79.7 ± 9.5 |
| Office | 90.6 ± 9.1 | 90.8 ± 9.3 | 90.5 ± 8.9 |
| Home | 89.9 ± 9.8 | 90.2 ± 9.8 | 89.7 ± 9.9 |
| Pulse pressure (24 hours by ABPM) | 49.6 ± 8.8 | 50.7 ± 8.2 | 48.6 ± 9.2 |
Data are mean ± standard deviation or number of patients (%).
Abbreviations: ABPM, ambulatory blood pressure monitoring; DBP, diastolic blood pressure; SBP, systolic blood pressure.